Abstract Background: The ability to maintain DNA integrity is a critical cellular function. DNA repair is conducted by distinct pathways of genes, many of which are thought to be altered in colorectal cancer. However, there has been little characterization of these pathways in colorectal cancer. Method: By using theTaqMan real-time quantitative PCR, RNA expression profiling of 20 DNA repair pathway genes was done in matched tumor and normal tissues from 52 patients with Dukes' C colorectal cancer. Results: The relative mRNA expression level across the 20 DNA repair pathway genes varied considerably, and the individual variability was also quite large, with an 85.4 median fold change in the tumor tissue genes and a 127.2 median fold change in the normal tissue genes. Tumornormal differential expression was found in 13 of 20 DNA repair pathway genes (only XPA had a lower RNA level in the tumor samples; the other 12 genes had significantly higher tumor levels, all P < 0.01). Coordinated expression of ERCC6, HMG1, MSH2, and POLB (R S z 0.60) was observed in the tumor tissues (all P < 0.001). Apoptosis index was not correlated with expression of the 20 DNA repair pathway genes. MLH1 and XRCC1 RNA expression was correlated with microsatellite instability status (P = 0.045 and 0.020, respectively). An inverse correlation was found between tumor MLH1 RNA expression and MLH1 DNA methylation (P = 0.003). Conclusion: Our study provides an initial characterization of the DNA repair pathways for understanding the cellular DNA damage/repair system in human colorectal cancer.
DNA repair is an important process to maintain the integrity of DNA sequence. It seems to contribute to tumorigenesis and is also a mechanism for tumor resistance to chemotherapy (1, 2) . Cellular repair of DNA is composed of several distinct pathways, which includes reversion repair, base excision repair, nucleotide excision repair (NER), mismatch repair (MMR), and DNA double-strand break repair (1, 3, 4) . Of these DNA repair pathways, NER is a multistep process capable of removing a variety of DNA distorting lesions from prokaryotic and eukaryotic genomes. In eukaryotic cells, the process requires >30 proteins to perform the different steps (1), i.e., recognition of DNA damage, single-strand incisions and excision of the lesion-containing DNA fragment, and DNA repair synthesis/ ligation. It has been shown that loss of function of several DNA repair genes is associated with increasing cancer risk, and the resistance to platinum-based drugs has also been associated with altered expression in base excision repair, NER, or MMR (3, 5 -7) .
In the DNA repair system, the translesional synthetic DNA polymerases POLB and POLH are paradoxically associated with DNA damage recognition protein HMG1 (8, 9) . HMG1 binds preferentially to the platinated fork-like synthetic DNA and inhibits the translesional synthesis, which is in contrast to the function of POLB and POLH. Furthermore, defects in DNA mismatch repair system can result in low resistance/high sensitivity of tumor cells to radiation or platinum drug -based chemotherapy (10, 11) , and an active MMR system can also lead to tumor cell death via the formation of futile cycles of translesional synthesis past cisplatin-DNA adducts followed by removal of the newly synthesized DNA (7, 11) .
The DNA repair pathway is under the regulation of multiple cellular processes, which can be crucial determinants to the fate of tumor cells exposed to DNA-damaging agents: resistance or apoptosis. It has been known that TP53 is a potent mediator of cellular responses against genotoxic insults and exerts its effect on the DNA repair pathway in sequence-specific DNAbinding mode primarily at the transcriptional level (12 -14) . In addition to its role in regulating cell cycle arrest and apoptosis, TP53 is also known to be involved in regulating DNA repair mechanisms through the induction of P53R2 (14) , a ribonucleotide reductase subunit, and may also directly participate in repair by promoting annealing of ssDNAs and rejoining double-stranded breaks. Other sensors or regulators of the DNA repair pathway, such as ATM, ATR, and RAD9, involved in DNA-damage signaling (15 -17) , were also included in the present study to determine any potential association between these regulators and tumor cell apoptosis.
In addition, defects in the DNA mismatch repair machinery can lead to instability of short tandem nucleotide repeats, called microsatellite instability (MSI). MSI is typical of hereditary nonpolyposis colorectal cancer that accounts for 2% to 3% of all colorectal carcinomas (18) , but MSI has also been identified in 10% to 15% of sporadic colorectal carcinomas in which constitutional mutations of MLH1 and MSH2 are rarely found (19, 20) . MSI is frequently due to MLH1 promoter hypermethylation (21, 22) . It has been widely shown that loss of MMR protein expression in tumor tissue may correlate with MSI (23, 24) . Therefore, the association between MSI status and gene expression of the DNA repair pathway is important to investigate for cellular DNA repair function.
Most studies have been conducted to evaluate specific DNA repair genes. In this study, we have profiled the RNA expression 
Materials and Methods
Patients and samples. In this study, genomic DNA and total RNA samples were prepared from tumor specimens and paired nonmalignant tissues of 52 consecutive patients with Dukes' C colorectal cancer undergoing colorectal surgery at Barnes Jewish Hospital. The age of the patients ranged from 32 to 96 years (median 69 years); 29 males and 23 females were included. Dissected specimens were snap frozen in liquid nitrogen immediately after surgery and stored at À80jC. None of the patients had received preoperative radiation or chemotherapy. Histologic examination was done in all of the cases to evaluate tumor histotype (41 enteric and 11 mucinous) and grade of differentiation (1, 38, and 13 in grade 1, 2, and 3, respectively) according to WHO criteria. Twenty-seven tumors were localized in the right colon, 19 in the left colon, and the remaining 6 were localized in the rectum. Written informed consent was obtained from all patients to bank tumor tissue and to perform genetic analysis. This study was approved by the Washington University Human Subjects Committee.
Extraction of genomic DNA and cellular total RNA. The tumor specimens selected for DNA and RNA isolation had high tumor cellularities (median 86% with a range of 65-95%). Tissue total RNA was isolated with the TRIzol RNA isolation kit (Invitrogen, Carlsbad, CA). The quality of RNA (A 260/280 >1.8; clear RNA bands for 28S, 18S, and 5S) was confirmed in the Siteman Cancer Center Tissue Procurement Core. Genomic DNA was extracted with Qiagen DNeasy Tissue kit (Qiagen, Hilden, Germany).
Quantitative real-time reverse transcription-PCR. Two-step reverse transcription-PCR was conducted in this study. First, cDNA was synthesized in a 20 AL reaction containing 5 Ag of total RNA, 0.5 Ag of oligo(dT) 20 VN primer, and 100 units of StrataScript reverse transcriptase (Stratagene, La Jolla, CA). The cDNA samples were then diluted to a concentration of 10 ng total RNA/AL. Ten-microliter reaction mixture for real-time PCR was composed of 5 AL of 2Â TaqMan universal PCR master mix (Applied Biosystems, Foster City, CA), 3 AL primer and probe mix (600 nmol/L each forward and reverse primers and 100 nmol/L specific TaqMan probe), and 2 AL cDNA (20 ng). All real-time PCR assays were done in triplicate on an ABI PRISM 7900HT Sequence Detector System (Applied Biosystems) according to the following program: 50jC for 2 minutes, 95jC for 10 minutes, 40 cycles at 95jC for 20 seconds, and at 60jC for 1 minute. Primers and TaqMan probes used in this study were designed using Primer Express version 1.5 (Applied Biosystems). The sequence of primers and probes specific for each gene are displayed in Table 1 . The specificity of each primer/probe set was determined with a pretest showing the specific amplification for a specific gene by gel visualization. Measurement of relative expression of mRNA. Relative mRNA expression level of each gene was calculated by a curve-fit method (instead of the DDC T method), which uses nonlinear regression to calculate the transcript abundance in each sample based on the kinetic raw data of fluorescence intensity at each cycle during the PCR reaction (25) . Because of a wide range of the standard curve slope (À2.9 to À3.8) for the 21 genes in this study, the DDC T method was not suitable to analyze relative RNA expression level of these genes. A mathematical regression model for simulation of sigmoid curve was used as follows (25) :
, where R n is backgroundsubtracted fluorescence intensity in real-time PCR at cycle n, R max is the maximal fluorescence intensity, n 1/2 is the cycle number when fluorescence intensity is half of the R max , and k is the slope factor of increase in fluorescence intensity. The regression analysis gives the variables R max , n 1/2 , and k. The initial value of each sample (R 0 ) equals
An internal reference gene, amyloid h precursor protein, which had nearly identical expression between colon tumor and normal tissues (46:31 copies/cell; ref. 26) , was used to control variation in RNA concentration across individual samples. Finally, the value of sample RNA level normalized to the internal reference gene was scaled to a 1Â sample so that the minimal level was 1 in the entire data set. Thus, the RNA expression level in this study is a unitless value or called arbitrary unit, relative to both the internal reference gene and the 1Â sample.
MLH1 methylation analysis. Genomic DNAs were first converted with treatment of sodium bisulfite as described previously (24) . After treatment, unmethylated cytosine residues are converted to thymine, whereas methylated cytosine residues are retained as cytosine. In addition, a human genomic DNA sample purchased from Promega (Madison, WI) was included either for negative control (unmethylated) when it was converted only by sodium bisulfite, or for positive control (high methylation) when it was treated first by the SssI methylase (New England Biolabs, Beverly, MA) and then converted by sodium bisulfite. The converted DNA samples underwent two rounds of amplification to obtain the gene-specific fragments for the pyrosequencing reaction, which was carried out to quantify the DNA methylation level. The firstround external PCR reaction were done using Amplitaq Gold PCR master mix (ABI, Foster City, CA), 5 pmol of each primer, and 10 ng of the bisulfite-converted genomic DNA in a 20 AL reaction. This external reaction was run for 40 cycles at 94jC, 55jC, and 72jC for 1 minute, whereas the second-round nested reaction was run for 55 cycles at 94jC for 30 seconds, 60jC for 30 seconds, and 72jC for 1 minute. The nested reaction was conducted with 5 ¶-biotinylated reverse or forward primer in a 20 AL reaction containing 2 AL of 1:5 diluted first-round PCR products, and 4 pmol of each primer. Pyrosequencing was done as previously described (27) , by using the pyrosequencing PSQ HS96A instrument and software (Biotage, Uppsala, Sweden). To validate specificity of the pyrosequencing reaction, the fragment-only, pyrosequencing-primer-only, and no-primer and no-fragment reactions were included for negative control. The MLH1 methylation primers were listed in Table 2 . Finally, the function of allele quantification in the pyrosequencing PSQ HS96A system is capable of quantifying the DNA methylation level for each CpG locus in the DNA samples. The DNA methylation levels were calculated as ratio of the base C to T peaks at a given CpG site in pyrograms. The average of three experiments was taken for the DNA methylation level of each CpG locus. When the DNA methylation level (expressed as average of multiple sites) was <5%, it is defined as unmethylated. Otherwise, 5% to 20% is denoted as low methylation, 21% to 50% as medium methylation, and >50% as high methylation.
MSI analysis. Analysis of MSI status in genomic DNA samples was done as previously described (28), using the panel of five consensus markers recommended for the detection of MSI in colorectal cancer (29) . This panel of markers includes three dinucleotide markers (D2S123, D5S346, and D17S250) and two mononucleotide markers (BAT25 and BAT26). Samples were classified as MSI-high if instability was detected at two or more consensus markers, MSI-low if instability was confined to only one consensus marker, and microsatellite stable if none of the consensus markers revealed instability. The data for the 52 tumors have been previously reported (30) . Statistical analysis. Descriptive statistical analyses were done using the software STATISTICA from StatSoft, Inc. (Tulsa, OK). The difference in RNA expression between paired tumor and normal samples was evaluated using Wilcoxon matched-pair test. The association of patient's phenotypes (e.g., age, gender, tumor location, DNA methylation, or MSI status) to RNA expression level was evaluated with either the Mann-Whitney test or the Kruskal-Wallis test. Spearman rank correlations were used to compare continuous variables.
Results
Differential expression of the pathway genes. Many of the pathway genes (65%) were differentially expressed between tumor and normal tissues. One gene (XPA) had a significantly lower mRNA expression level in the 52 colorectal tumor tissues than in the matched adjacent normal tissues (median 0.78-fold lower, P = 0.004); but 12 of 20 (60%) DNA repair pathway genes studied had significantly higher mRNA level in the tumors than in the normal tissues (median range 1.36-to 2.85-fold higher, all P < 0.01). There were no significant differences between paired tumor and normal samples in 7 of 20 genes (35%, P = 0.061-0.682; Table 3 ). Furthermore, patients were classified according to a tumor-normal ratio of <0.8, 0.8-1.2, or >1.2 for each gene. A category list is presented in Table 3 to further address the differential expression of the 20 pathway genes.
Variability of mRNA expression of the pathway genes. Variability for each gene was large (Fig. 1) ; the coefficient of variance ranged from 43.4% to 155.0% (median 88.4%) in the tumor tissues and from 41.6% to 166.6% (median 110.4%) in the normal tissues. Similarly, the fold change of gene expression in the 52 colorectal cancer patients was wide for most of the 20 DNA repair pathway genes; it ranged from ATM 11.1 to MLH1 2,209.3 (median 85.4) in the tumor and also from ATM 8.0 to MLH1 4,761.5 (median 127.2) in the normal tissue. Although some genes had a significantly different mRNA level in the tumors, not all patients fell into a single category of either tumor-normal ratio of <0.8 or >1.2 (Table 3) . Like the RNA level itself, the tumor-normal ratio of the 52 patients for each gene also varied widely, with the coefficient of variance from 63.7% to 274.0% (median 142.9%) and the fold change from 28.2 to 4,825.3 (median 246.5).
Relative expression of the pathway genes. By scaling entire data set to a 1Â sample, we were able to look at relative expression across multiple genes. As shown in Fig. 1 and Table 3 , the relative expression level across the 20 DNA repair genes varied largely. The median mRNA expression level in the tumor samples ranged from the lowest MSH6 (1.78 Â 10 2 units) to the highest HMG1 (1.18 Â 10 6 units), representing a 6,653-fold change; and in the normal samples, again MSH6 (1.50 Â 10 2 units) was the lowest one, and the highest one was XPA (7.13 Â 10 5 units), representing a 4,768-fold change (Table 3 ). The median tumornormal ratios for the 20 genes ranged from 0.78 to 2.85.
Correlation of the pathway genes. Coordinated expression was noted among the 20 DNA repair pathway genes. For instance, ERCC6, HMG1, MSH2, and POLB each had a Spearman rank correlation score of R S z 0.60 with three other Research.
on July 12, 2017. © 2006 American Association for Cancer clincancerres.aacrjournals.org Downloaded from genes in the colon tumor tissues (all P < 0.001; Table 4 ). Moreover, among the nine NER genes evaluated, each pair of ERCC3 and ERCC4, ERCC4 and ERCC6, and XPC and ERCC3 had a closer correlation in the RNA expression than other NER genes (R S > 0.60, P < 0.001). The three MMR genes in this study had no significant correlations in the RNA expression.
MSI status, MLH1 methylation and apoptosis index. Ten of the 52 tumors (19%) were classified as MSI-high. Four tumors (8%) showed instability at only one locus (classified as MSI-L), and 38 (73%) showed no instability at any of the five loci examined (classified as microsatellite stable). The median tumor RNA expressions of MLH1 and XRCC1 were significantly lower in patients with MSI-high than those with microsatellite stable (MLH1: 177,332 versus 362,339 units, XRCC1: 138,754 versus 310,419 units; Mann-Whitney U test, P = 0.04 and 0.02 for MLH1 and XRCC1, respectively), but another two MMR genes (MSH2 and MSH6) and other DNA repair genes had no statistical difference (Fig. 2) . In the DNA methylation experiment, five CpG dinucleotide loci in MLH1 promoter region (À248 to À222 from the transcriptional start site) were evaluated and a total of 20 tumors were defined as MLH1 methylated, of which nine, five, and six tumors had high methylation (64.9-90.6%, median 80.0%), medium methylation (21.1-44.0%, median 31.4%), and low methylation (5.0-16.1%, median 7.2%), respectively. A reciprocal relationship between the average DNA methylation degree and the RNA level was observed for MLH1 in the 20 methylated tumors (R S = À0.624, P = 0.003; Fig. 3 ). Furthermore, there was concordance between the MLH1 high-methylation tumors (89%; eight of nine) and the MSI-high tumors (80%; 8 of 10) in colorectal cancer patients (Table 5) . Forty-six tumors had available sections for the TUNEL staining (used as apoptosis index), of which 25 showed low apoptosis (average apoptosis index score was <1.5) and 21 high apoptosis (apoptosis index score equal to or >1.5). All 20 pathway genes had no obvious difference in their RNA level between the high and low apoptosis tumors (all P > 0.1, Mann-Whitney U test); and there was no difference in apoptosis index between MSI-high and microsatellite stable tumors.
Association between RNA level and clinicopathologic features. No significant association between RNA level was found by patient age, gender, tumor location, cellularity, histologic type, or grade of tumor differentiation for any of the 20 pathway genes. In addition, no association between RNA level and the apoptosis index was observed for all genes analyzed in this study, including the four coordinated genes (ERCC6, HMG1, MSH2, and POLB). No patient outcome data are available for further analysis of correlation with the RNA level or methylation level.
Discussion
The DNA repair system is important for maintaining the stability of normal genomic function of cells. In human cancer, one of the most promising molecular phenotypes investigated to date is MSI and the high MSI phenotype has been suggested to be involved in development of colorectal cancer through DNA repair defects, particularly in MMR genes such as MLH1. Approximately 15% of colorectal cancers are characterized by genomic MSI, reflecting inactivation of the MMR genes (31, 32) . Our study showed an inverse correlation between the MLH1 DNA methylation and RNA expression (Fig. 3) , and between the MSI status and the RNA expression level for the MMR gene MLH1 (Fig. 2) , which is consistent with the concept of inactivation of cellular DNA repair function (e.g., through DNA methylation), leading to genomic MSI. This association is further confirmed by concordance between MLH1 methylation and MSI-high in the colorectal tumors. Our data did not reveal a clear RNA-MSI relationship for other MMR genes (MSH2 and MSH6), likely reflecting additional functional influences of these genes. Recent studies have shown that the MMR proteins MSH2 and MSH6 functionally interact and MSH6 is degraded in the absence of its binding partner (33) . Thus, the mechanisms that cause genomic MSI may not be only through transcriptional regulation of the MMR genes. Also, our data did not show any associations between tumor apoptosis, MSI status, and the RNA level of DNA repair pathway genes, suggesting that tumor apoptosis activity, and similarly the response of tumor cells to DNA-damaging agents, may not rely solely on gene activity of the DNA repair pathway. Previous studies have shown that TP53 is required for efficient NER processing of UV-induced DNA lesions (12 -14, 34) and in the present study TP53 was overexpressed in the colon cancer tissues. Although no correlation was observed between TP53 and the other 19 DNA repair pathway genes in our study (P > 0.05), functional TP53 sure has critical interaction with many of the pathway genes and MDM2 can largely affect protein level of the functional TP53 (35) . Besides, our data showed a large interpatient variability of the RNA expression of 20 DNA repair pathway genes, suggesting a substantial source of variable chemosensitivity in colorectal cancer. With the large variability of the pathway genes, individualized cancer therapy will be needed for clinical practice where cancer patients have a wide range of response to certain compounds, from no response at all to fatal outcome (36) .
DNA repair subpathways are a multistep, multielement process to remove the damaged DNA section and to resynthesize that part of the DNA strand, except for reversion repair pathways. Thus, interplay involved in multiple genes is critical and more informative for identifying genes responsible for chemosensitivity. In the past 10 years, high-throughput approaches for gene expression profiling have defined key determinants that may play a role in prediction of cancer patient outcome, as well as response to chemotherapy (37 -39) . For instance, Wang et al. (37) , using microarray technology, have identified a 23-gene signature that predicts recurrence in Dukes' B patients with 78% overall accuracy. Murakami et al. (39) used cDNA microarray technology to examine the effect of UVB irradiation on 588 cancer-related genes in human keratinocytes and identified several UV-reactive genes, including ERCC1 and XRCC1. In our study, with the Spearman rank correlation test, a variety of correlations were observed among the 20 DNA repair pathway genes in the colon cancer tissues. Those genes with a higher Spearman correlation score (>0.60; Fig. 1 ) may have coregulation or coordinated expression in a certain mode. Although all highly correlated genes are not on the same chromosome, they may share regulatory domains or other transacting mechanisms. For example, ERCC4, located in chromosome 16, is required for incision of the damaged DNA backbone at the 5 ¶ side of the lesion in the NER process. The 3 ¶ side incision by ERCC5 requires ERCC6, which is located on chromosome 10 and had a Spearman score of 0.67 with ERCC4. Thus, these two genes could have a certain common transacting mechanism for DNA repair. Moreover, HMG1 is located on chromosome 13 and POLB on chromosome 8, and they had a Spearman correlation score of 0.67. Those two genes participate in the DNA damage recognition and the translesional synthesis process, respectively. A positive correlation for these two genes may be suggestive of a synergetic association between them to fulfill DNA repair, but is contradictive to the fact that HMG1 inhibits the translesional synthesis by POLB and POLH. These results from clustering or correlation analysis will need to be further validated with functional studies and/or clinical trails designed to use expression profiles of these genes in tumors to predict response to DNA-damaging drugs.
Defects in DNA repair give rise to hypersensitivity of tumors to DNA damage, and overexpression of DNA repair genes render tumor resistance to DNA-damaging agents. A recent study has reported that low levels of the NER enzymes ERCC1, ERCC4, and XPA are related to the favorable response of testis tumors to cisplatin-based chemotherapy (40). Ferry et al. (6) have also shown that several NER genes, including ERCC1, are constitutively overexpressed in the highly cisplatin-resistant cell line C200 compared with the sensitive parental A2780 cells. In Fig. 3 . Correlation between the MLH1 RNA level (log scale) and DNA methylation in the MLH1-methylated (>5%) tumors. Research.
on July 12, 2017. © 2006 American Association for Cancer clincancerres.aacrjournals.org Downloaded from our study, differential expression analysis of the DNA repair pathway genes indicates that 12 of the 20 pathway genes had increased expression in the tumor tissues, whereas only one (XPA) was higher in the nonmalignant tissues (Table 2) . It is noted that a number of the DNA repair pathway genes were overexpressed, which may contribute at least in part to low response rates from single platinum agent treatment of colorectal cancer. On the other hand, the resistance of colorectal cancer to platinum drugs may not likely come from XPA in most patients with colorectal cancers (27 of 52, 52%) because of its lower tumor RNA expression level. Meanwhile, ATR involvement in platinum resistance has been suggested (15, 17) , and in our study the ATR mRNA expression was significantly overexpressed in the colorectal tumor tissues (1.88-fold, P < 0.001). Thus, ATR may become a molecular marker for prediction of response in platinum-based chemotherapies.
Development of intrinsic or acquired resistance to DNAdamaging drugs may rely on several elements, such as the gene activity of the DNA repair pathway, defects in whole cell uptake and adduct formation, and the so-called secondary lesions (DNA strand breaks and apoptosis; refs. 2, 41, 42). For instance, it has been shown that oxaliplatin forms fewer DNA adducts than cisplatin, and oxaliplatin adducts are poorly recognized by the MMR system (2) . Moreover, the ability of oxaliplatin adducts to activate signal transduction pathways, ultimately leading to apoptotic DNA fragmentation, differs from cisplatin (2, 3, 41, 42) . In answer to the issue of chemosensitivity to DNA-damaging agents, by analyzing the differential expression, individual variability, and coexpression, our RNA expression profiling study has provided an initial characterization of the DNA repair pathways to aid in further understanding of the cellular DNA damage/repair system in human colorectal cancer.
